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Identification of pyrrolopyrimidine 
derivative PP-13 as a novel 
microtubule-destabilizing agent 
with promising anticancer 
properties
Pauline Gilson1,2, Fernando Josa-Prado3, Claire Beauvineau4, Delphine Naud-Martin4,  
Laetitia Vanwonterghem1, Florence Mahuteau-Betzer4, Alexis Moreno  5, Pierre Falson5, 
Laurence Lafanechère1, Véronique Frachet1,6, Jean-Luc Coll  1, Jose Fernando Díaz  3, 
Amandine Hurbin  1 & Benoit Busser  1,2
Despite the emergence of targeted therapies and immunotherapy, chemotherapy remains the gold-
standard for the treatment of most patients with solid malignancies. Spindle poisons that interfere 
with microtubule dynamics are commonly used in chemotherapy drug combinations. However, 
their troublesome side effects and the emergence of chemoresistance highlight the need for 
identifying alternative agents. We performed a high throughput cell-based screening and selected a 
pyrrolopyrimidine molecule (named PP-13). In the present study, we evaluated its anticancer properties 
in vitro and in vivo. We showed that PP-13 exerted cytotoxic effects on various cancer cells, including 
those resistant to current targeted therapies and chemotherapies. PP-13 induced a transient mitotic 
blockade by interfering with both mitotic spindle organization and microtubule dynamics and finally 
led to mitotic slippage, aneuploidy and direct apoptotic death. PP-13 was identified as a microtubule-
targeting agent that binds directly to the colchicine site in β-tubulin. Interestingly, PP-13 overcame 
the multidrug-resistant cancer cell phenotype and significantly reduced tumour growth and metastatic 
invasiveness without any noticeable toxicity for the chicken embryo in vivo. Overall, PP-13 appears to 
be a novel synthetic microtubule inhibitor with interesting anticancer properties and could be further 
investigated as a potent alternative for the management of malignancies including chemoresistant 
ones.
In the last two decades, advances in the understanding of carcinogenesis have revolutionized the management 
of cancer patients with the development of targeted therapies and immunotherapy. Identification of genetic 
alterations in subsets of cancers leading to different subcellular signals of tumour growth and progression elic-
ited the clinical use of oncogene-targeted therapies for patients harbouring such anomalies1–4. In lung cancers 
with EGFR-activating mutations, anti-EGFR therapies, including gefitinib, erlotinib, and afatinib, have been 
shown to improve progression-free survival and were approved as first-line options5. However, despite the ini-
tial response, resistance mechanisms almost inevitably ensue and limit the long-term potency of targeted ther-
apies6, 7. Moreover, efforts are still needed for the management of patients without targetable oncogenic driver 
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mutations representing 60% of non-small cell lung cancer (NSCLC) cases8. Immunotherapies, especially immune 
checkpoint inhibitors, are emerging for cancer therapy and have the advantage of providing durable responses 
and improved patient prognosis9–11; however, intrinsic resistance for numerous tumour types has also restricted 
their use12. Therefore, non-selective chemotherapy remains a gold-standard treatment for almost all patients 
with advanced solid cancers. Spindle poisons that interfere with microtubule dynamics represent a major class of 
conventional chemotherapy drugs commonly used in combination for cancer treatments8. Among the approved 
microtubule-targeting agents, taxanes and vinca-alkaloids that respectively stabilize and depolymerize micro-
tubules are widely used. However, their troublesome side effects, especially myelosuppression and peripheral 
neurotoxicity, and the emergence of chemoresistance make essential the development of alternative agents13.
With the aim to identify new chemical compounds able to abolish resistance to apoptosis in NSCLC, we 
have conducted a high-throughput cell-based screening of more than 7500 molecules. We have selected a small 
molecule belonging to the pyrrolopyrimidine family (PP-13) that strongly induced apoptosis. Here, we show that 
PP-13 is cytotoxic for a large panel of human cancer cell lines. The PP-13 molecule induced mitotic cell blockade 
by impairing both mitotic microtubule organization and dynamics and was identified as a microtubule-targeting 
agent that selectively binds to the colchicine-binding site on β-tubulin. Contrary to conventional spindle poisons 
used for cancer treatment, PP-13 overcame multidrug resistance (MDR). This molecule also showed in vivo anti-
tumour activity without any noticeable toxicity in the chicken embryo.
Results
Identification of a new molecule inhibiting the proliferation of various human cancer cells. To 
identify new potent chemical molecules that induce apoptosis in a resistant NSCLC cell model, we designed a 
high-throughput cell-based assay on H358 NSCLC cells that we have previously described as a model of resist-
ance to apoptosis induced by serum starvation14, 15. We screened 7520 compounds at a final concentration of 2.5 
µmol.L−1. Among the 71 chemical molecules identified as restoring more than 49% of apoptosis, one pyrrol-
opyrimidine derivative, PP-13 (ethyl 4-((4-(benzylamino)-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)
benzoate), was finally selected for further biological and biochemical characterization owing to its high cytotoxic 
effects (Fig. 1A).
We first evaluated the ability of PP-13 to inhibit growth of human NSCLC cell lines (H358, H322, A549, 
H1975, H3255, H1650, PC9 and NCI-H460) harbouring various forms of TP53, KRAS and EGFR status 
(Supplementary Fig. S1). NSCLC cells treated with increasing concentrations of PP-13 showed a drastic inhi-
bition of their viability regardless of their mutational status (Fig. 1B upper panel). Concentration values inhib-
iting cell growth by 50% (IC50) ranged from 76 to 255 nmol.L−1 (Fig. 1B lower panel). Interestingly, PP-13 was 
effective both on NSCLC cell lines resistant (H1650, H1975) and sensitive (PC9, H3255) to anti-EGFR-targeted 
therapies. To determine if PP-13 activity was specific to NSCLC cells, we used other representative human can-
cer cell lines from various origins (colorectal cancer cell lines HCT116 and HT29; breast cancer cell line MCF7; 
prostate cancer cell line PC3; cervical cancer cell line HeLa; melanoma cell lines colo829, A375, A7 and SkMel-2) 
(Fig. 1C). Similar to the results obtained in NSCLC cells, the IC50 concentrations for PP-13 ranged from 67 to 145 
nmol.L-1, except for MCF7 cells, which resisted to PP-13. PP-13 also reduced the viability of normal human foetal 
lung fibroblasts, MRC5, and human keratinocyte, HaCat, with an IC50 of about 70 nmol.L-1 in the same range as 
for cancer cell lines (Fig. 1D). Similar effects were observed in these cell lines with the antimitotic chemother-
apy paclitaxel currently used for breast cancers, ovarian cancers, or NSCLC treatment (Supplementary Fig. S2). 
Although IC50 concentrations for PP-13 were higher than those for paclitaxel in cancer cell lines, they were in the 
nanomolar range (Fig. 1 and Supplementary Fig. S2). In addition, MRC5 and HaCat normal cells appeared to be 
less sensitive to PP-13 compared to paclitaxel (Fig. 1D and Supplementary Fig. S2C). Taken together, these data 
suggest that PP-13 exerts an interesting cytotoxic activity in a wide panel of cancer cell lines.
PP-13 overcomes the multidrug-resistant (MDR) phenotype in cancer cells. The overexpression 
of efflux pumps or multidrug transporters confers cell resistance to many drugs and represents the major expla-
nation for the mechanism of tumour cell chemoresistance to spindle poisons16. To determine the activity of PP-13 
in an MDR phenotype context, we compared the effects of PP-13 on the proliferation of drug-sensitive cells 
with those on their drug-resistant counterparts that overexpress P-glycoprotein, BCRP, MRP1, or MRP2 efflux 
transporters (Table 1). PP-13 exerted similar cytotoxic effects in drug-sensitive cells and MDR cells, with an IC50 
ranging between 280 nmol.L−1 and 1 µmol.L−1. This result indicates that PP-13 is not a substrate of these drug 
transporters. This contrasts with the active efflux of paclitaxel by P-glycoprotein, with a ratio of 375 between the 
IC50 of drug-sensitive and P-glycoprotein-overexpressing cells (Table 1 and ref. 16).
PP-13 induces mitotic blockade in cancer cells. Two cell lines presenting high sensitivity to PP-13 were 
chosen for further investigation: the H358 NSCLC cells that were used for the initial high-throughput cell-based 
screening model and the HeLa carcinoma cell line, with IC50 values of 170 and 120 nmol.L−1, respectively. The 
effects of PP-13 on cell cycle distribution were assessed over time by flow cytometry in these cells. Both H358 and 
HeLa cells treated with PP-13 at the IC50 concentration transiently accumulated in the mitosis stage (Fig. 2A,B). 
Thirty-two percent of cells were found in mitosis after 18 h of PP-13 exposure compared to approximately 2% 
of vehicle-treated cells (Fig. 2A,B, and Supplementary Fig. S3). The percentage of mitotic cells then gradually 
decreased, concomitantly with the accumulation of apoptotic cells in the sub-G1 fraction. After 72 h of PP-13 
treatment, approximately 20% of cells underwent apoptosis compared to only 1% of the vehicle-treated cells. 
Consistent with the progressive increase in the apoptotic sub-G1 cells, PP-13 strongly induced the cleavage of 
caspase-3 in both H358 and HeLa cells (Fig. 2C and Supplementary Fig. S4). Although PP-13 effect was not as 
strong as that of paclitaxel17 (Supplementary Fig. S2), these results showed that PP-13 induced mitotic cell arrest, 
which ultimately led to caspase-dependent apoptosis.
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PP-13 interferes with both mitotic microtubule organization and spindle pole integrity. Since 
any perturbation of the microtubule dynamic balance can lead to microtubule disorganization and mitotic cell 
cycle arrest18, we investigated the effects of PP-13 on microtubules in HeLa cells by immunofluorescence. After a 
24h treatment with PP-13, HeLa cells presented a microtubule organization in interphase similar to that of control 
cells (Fig. 3A). During metaphase, control cells typically showed 2 symmetrical and fusiform bipolar spindles with 
well-aligned chromosomes at the mid-plate (Fig. 3B). In contrast, PP-13-driven mitotically arrested cells showed 
short and multipolar spindles associated with strong defects in chromosome congression and alignment, suggest-
ing a prometaphase blockade. In agreement with the flow cytometry analysis, the percentage of cells in interphase 
Figure 1. PP-13 significantly inhibited the proliferation of human cancer cell lines. (A) Chemical structure of 
PP-13. (B–D) The MTT assays in NSCLC cells (B), in other representative cancer cell lines from various origins 
(C), and in human foetal lung fibroblast MRC5 cells and in human keratinocyte HaCat cells (D), treated with 
the indicated concentrations of PP-13 for 72 h. Lower panels: PP-13 concentrations required to inhibit cell 
growth by 50% (IC50) at 72 h. Data represent the mean ± SD of three independent experiments (in nmol.L−1).
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decreased in response to PP-13 treatment, whereas abnormal mitotic cells accumulated (Fig. 3C). Moreover, 
huge and polynucleated cells in pseudo-interphase were also identified and accounted for almost 47% of total 
cells. Abnormal mitotic cells showed a mean of 2–4 spindle poles (Fig. 3D). Similar observations were made in 
Cell lines IC50 of PP-13 IC50 of Paclitaxel
HEK293 780 nmol.L−1 nt
HEK293 overexpressing MRP2 transporter 700 nmol.L−1 nt
NIH-3T3 490 nmol.L−1 40 nmol.L−1
NIH-3T3 overexpressing P-glycoprotein transporter 490 nmol.L−1 >15 µmol.L−1
HEK293 1000 nmol.L−1 5 nmol.L−1
HEK293 overexpressing MRP1 transporter 650 nmol.L−1 6.3 nmol.L−1
HEK293 430 nmol.L−1 75 nmol.L−1
HEK293 overexpressing BCRP transporter 280 nmol.L−1 93 nmol.L−1
Table 1. PP-13 overcomes efflux-mediated chemoresistance. The effects of PP-13 and paclitaxel on cell viability 
were determined by MTT assays. Concentrations required to inhibit cell growth by 50% (IC50) at 72 h in drug-
sensitive cell lines and their multidrug-resistant counterparts overexpressing P-glycoprotein, MRP1, MRP2, or 
BCRP transporters. Data are the mean of triplicates. nt: not tested.
Figure 2. PP-13 interferes with the mitotic progression of H358 NSCLC and HeLa cells. H358 and HeLa cells 
were treated with PP-13 at 170 and 120 nmol.L−1, respectively. (A) The cell-cycle phases were determined 
by flow cytometry over time as indicated. The histograms represent the mean of the percentage of cells in 
each phase of the cell cycle (n = 3 independent experiments). (B) Graphical representation of the percentage 
of mitotic and sub-G1 cells in control and PP-13-treated cells. Data are presented as the mean ± SD of ≥ 3 
independent experiments (*****p < 0.01; ****0.01 < p < 0.02; ***0.02 < p < 0.03; **0.03 < p < 0.04, 
*0.04 < p < 0.05 compared to control cells). (C) Cleavage of caspase 3 was evaluated by western blotting. Actin 
was used as a loading control. For the sake of clarity, cropped blots are shown. Full-length blots are presented in 
Supplementary Fig. S4.
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PP-13-treated H358 cells, but the cells mostly showed more than 5 spindles poles and no significant augmentation 
of polynucleated cells (Supplementary Fig. S5). Since aberrant multipolar spindles are frequently associated with 
supernumerary centrosomes19, we quantified the microtubule-organizing centres (MTOCs) in mitotic cells using 
γ-tubulin staining (Fig. 3E and F). Under PP-13 treatment, HeLa cells displayed a variable number of γ-tubulin 
dots, with an average of 2–3 γ-tubulin dots per cell, while control cells normally harboured 2 γ-tubulin dots. In 
contrast, in H358 cells, the number of γ-tubulin dots was comparable to that of control cells (Supplementary 
Fig. S5). We next examined the centrosome composition with centrin-2, a specific marker for centrioles. Control 
cells showed each centrosome displaying a pair of cohesive centrioles (Fig. 3E), whereas PP-13-treated cells with 
more than 2 spindle poles presented variable numbers of centrin-2 dots (0, 1 or 2 dots per MTOC), likely because 
Figure 3. PP-13 interferes with mitotic spindle architecture and centrosome formation. HeLa cells were treated 
with or without 120 nmol.L−1 PP-13 for 24 h. (A,B) Representative confocal microscopy images of microtubules 
in cells in interphase (A) or mitosis (B). In red: α-tubulin, in blue: DNA staining with DAPI. (C) Quantification 
of interphase, mitotic, apoptotic and polynucleated cells. At least 550 cells were randomly chosen and scored in 
each condition. *p = 0.0495; NS, not significant. (D) Quantification of spindle poles per mitotic cell. According 
to a conventional nomenclature60, type I and II spindles are bipolar (n = 2) with at least one uncongressed 
chromosome; type III spindles are monopolar (n = 1), whereas multipolar spindles presented more than two 
poles (n > 2). At least 100 mitotic cells were randomly chosen and scored in each condition. n: number of 
mitotic spindles. (E) Confocal microscopy images showing centrosome organization and centrin-2 repartition 
in mitotic cells. Insets represent a zoom of the boxed area. In red: γ-tubulin, in green: centrin-2, in blue: DNA 
staining with DAPI, a-e: centrioles. (F) Quantification of γ-tubulin dots per mitotic cell. At least 100 mitotic 
cells were randomly chosen and scored in each condition.
www.nature.com/scientificreports/
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of the disengagement of centriole pairs20. Overall, these observations showed that PP-13 induced mitotic spindle 
multipolarity and microtubule disorganization, resulting in prometaphase cell cycle arrest.
PP-13 activates the spindle assembly checkpoint followed by mitotic slippage, aneuploidy or 
direct apoptotic death. The spindle assembly checkpoint (SAC) is a safety mechanism assuring faithful 
chromosome segregation during cell division. The SAC is typically activated during prometaphase and delays 
anaphase onset until all chromosomes are well aligned and correctly attached to the mitotic spindle by kineto-
chores. Since the SAC complex is frequently involved in prometaphase arrest21, we evaluated the impact of PP-13 
on SAC activation by following the activation of BubR1, a major component of SAC (Fig. 4A and B). Time-lapse 
videomicroscopy of HeLa cells stably expressing BubR1-EGFP showed that the mean time of BubR1 activation 
in control cells was 1.60 ± 1.01 h, whereas it was more than 7.37 ± 2.79 h in PP-13-treated cells (Fig. 4A and B). 
Activation of BubR1 was thus approximately 5-times longer in PP-13-treated cells than in control cells, proba-
bly contributing to mitotic arrest. The fate of transiently arrested cells was next investigated by time-lapse vid-
eomicroscopy using HeLa cells stably expressing α-tubulin-EGFP and histone H2B-RFP (Fig. 4C and D). In 
control conditions, mitotic cells represented only 2% of cells and exhibited typical mitotic features (Fig. 4D and 
Supplementary Fig. S6). Under PP-13 treatment, different fates of abnormal mitotic cells were observed. Fifty 
percent of mitotic cells underwent apoptosis directly as evidenced by the emergence of membrane blebbing, chro-
matin condensation or apoptotic bodies (Fig. 4C and D, and Supplementary Fig. S7). Following prometaphase 
blockade, 35% of cells initiated aberrant cytokinesis with asymmetric cytoplasmic and chromosomal division 
(Fig. 4C and D, and Supplementary Fig. S8). This resulted in cell aneuploidy with the generation of non-viable 
cells or re-clustering, leading to the generation of polynucleated pseudo-interphase cells. In turn, cells either 
underwent cell death (94% of these cases), as indicated by the presence of micronuclei, nucleus hyperfragmenta-
tion or blebbing, or moved forward into mitosis (6% of these cases) (Fig. 4C and D, and Supplementary Fig. S9). 
Finally, a small fraction of cells died during interphase (13%) or slipped out of mitosis (2%). Similar defects were 
obtained with H358 cells, with the induction of either mitotic slippage (exit out of mitosis without cytokinesis, 
64% of cases), asymmetric division (24% of cases), or direct apoptotic death (12% of cases) (Supplementary 
Fig. S10). Altogether, these data showed that PP-13 induced an SAC-dependent prometaphase blockade leading 
to aneuploidy, mitotic slippage and cell death.
PP-13 directly targets tubulin and competes with colchicine for binding. The main molecular 
targets of PP-13 involved in SAC-dependent prometaphase blockade could be mitotic kinases or tubulin. We first 
performed a kinome assay to test the ability of PP-13 to inhibit a panel of more than 450 human protein kinases 
including mitotic kinases and relevant cancer mutant kinases. No kinase was inhibited at 1 or 10 µmol.L−1, sug-
gesting that PP-13 does not act as a kinase inhibitor (Supplementary Fig. S11). To evaluate whether tubulin is a 
target of PP-13, we performed an in vitro tubulin polymerization assay using pure tubulin. PP-13 did not delay 
the start of microtubule assembly but significantly reduced the microtubule polymerization speed and maximal 
polymerized tubulin rate in a dose-dependent manner (Fig. 5A). After 1 h, 5 µmol.L−1 of PP-13 decreased the 
tubulin polymer mass as much as 2.5 µmol.L−1 of colchicine. The microtubule-depolymerizing effect of PP-13 was 
confirmed by electron microscopy (Fig. 5B). No microtubule was observed in the presence of PP-13 or colchicine. 
These observations indicated that PP-13 directly targets tubulin and exerts potent depolymerizing effects in vitro.
Because the colchicine binding site is a major pocket for most of the microtubule destabilizers22, we investi-
gated the ability of PP-13 to bind to this site by competitive experiments with a reversible fluorescent colchicine 
analogue (MTC) whose binding to unassembled tubulin raises the fluorescence signal23, 24. In the conditions of 
the assay (absence of Mg+2 in the buffer), tubulin is in the dimeric state. Conditions were chosen to allow that 
roughly 50% of the colchicine binding sites in tubulin are occupied by MTC and 50% of them are free. In the 
presence of a competitor for the colchicine site, it will bind to the empty sites and the MTC binding equilibrium 
will be reshuffled resulting in a decreased intensity of the tubulin-bound MTC fluorescence in a dose-dependent 
manner, which was observed in Fig. 5C. Fifty µmol.L−1 of PP-13 reduced the fluorescence intensity by 56%. This 
displacement of MTC by PP-13 fits to a competitive model25 (Fig. 5D), demonstrating the ability of PP-13 to bind 
to the colchicine-binding site of tubulin. Based on the MTC binding constant (4.7 × 105 M−1), the binding con-
stant of PP-13 was calculated as previously described25 to be 9.3 × 104 M−1 (Fig. 5D).
PP-13 reduces tumour growth and metastasis invasion in vivo. To evaluate the antitumour activity 
of PP-13 in vivo, we used NSCLC H358 cells xenografted on chicken chorioallantoic membranes (CAM). Formed 
tumours were treated every 48 h with vehicle (0.5% DMSO), paclitaxel (50 µmol.L−1), or PP-13 (0.17 µmol.L−1) 
(Fig. 6A). Paclitaxel was used as a positive control and a concentration of 50 µmol.L−1 was chosen to induce 
significant tumour growth inhibition without toxicity for embryos. At day 19, tumours were recovered from the 
upper CAM and weighed. PP-13 significantly inhibited H358 tumour growth (Fig. 6B and C) compared to con-
trol. Importantly, the comparison of the number of dead chicken embryos in control and PP-13-treated eggs, as 
well as the analysis of embryos morphological or functional defects, indicated that PP-13 showed no noticeable 
toxicity in the chicken embryo (Supplementary Fig. S12). This suggests that in this model PP-13 is well tolerated 
at a dose sufficient to induce an anti-tumour effect. Analysis of the presence of H358 cells at the lower CAM by 
qPCR allowed for the accurate detection of tumour cell dissemination (Fig. 6D). At 0.17 µmol.L−1, PP-13 reduced 
the metastasis ability of H358 cells compared to control, suggesting that PP-13 inhibits invasion mechanisms.
Discussion
We have isolated a pyrrolopyrimidine derivative (PP-13) that is cytotoxic for several cancer cell lines in the same 
order of magnitude of concentrations as paclitaxel. MCF7 was the only cell line that resisted to both PP-13 and 
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Figure 4. PP-13 induces cell prometaphase arrest then asymmetric division or direct apoptotic death. BubR1-
EGFP HeLa cells (A,B) or α-tubulin-EGFP H2B-RFP HeLa cells (C,D) were treated with or without 120 nmol.
L−1 PP-13, and cells were followed over time with time-lapse videomicroscopy. Times are indicated on each 
picture. (A) Spindle assembly checkpoint (SAC) activation was analysed over time by following the activation of 
BubR1. (B) Time of BubR1 activation was estimated by time-lapse videomicroscopy, after following 10 control 
cells and 31 treated cells over time. Only 2/31 treated cells had BubR1 activation time less than 2 hours due to 
mitotic catastrophe. (C) Percentages of different cell fates induced by PP-13 treatment were estimated by time-
lapse videomicroscopy, after following 46 treated cells over time. (D) The cell division process was followed 
over time and representative pictures are shown. Control cells undergoing mitosis exhibit typical features of the 
different cell-cycle phases: a. interphase; b. prophase; c. metaphase; d. anaphase I; e. anaphase II; f. cytokinesis; 
g. interphase. PP-13 induces cell prometaphase arrest (h), then asymmetric division (i) or direct apoptotic death 
(j). Orange and blue arrows indicate blebbing and chromatin condensation respectively. Polynucleated cells 
generated from asymmetric division can initiate a second mitosis (k). In red: H2B-RFP, in green: α-tubulin-
EGFP.
www.nature.com/scientificreports/
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paclitaxel. One explanation could be the absence of caspase 3 in this cell line26. In addition, PP-13 seemed less 
toxic than paclitaxel for normal cells. In an attempt to decipher its mechanism of action, we carefully analysed 
its effect on the cell cycle. We found that PP-13 induced spindle multipolarity, chromosome missegregation and 
subsequent transient mitotic arrest in prometaphase in H358 NSCLC and HeLa cervical cancer cells. Treated 
cells displayed supernumerary spindle poles likely because of a loss of spindle pole integrity and premature cent-
riole pair disengagement given the atypical composition of MTOCs (0–2 centrioles per pole). A similar aberrant 
phenotype following mitotic blockade has been described for cells treated with nocodazole, colcemid or nitrous 
oxide20. The consequences of PP-13 treatment on the number of mitotic spindles and spindle poles were found 
to be highly variable according to the cell type. PP-13-treated HeLa cells exhibited 2–4 mitotic spindles and 2–3 
MTOCs, whereas PP-13-treated H358 cells displayed more than 5 mitotic spindles. The number of centrosomes 
of these latter cells appeared, however, normal, as assessed by γ-tubulin staining, which was equivalent to the 
staining of the DMSO-treated control cells. This could suggest that either the PP-13 molecular targets or mitotic 
checkpoints differ depending on the cell type. In addition, PP-13 induced an accumulation of polynucleated cells 
in the G1-like stage in HeLa cells and not in H358 cells. These different mitotic phenotypes observed between 
the different cell types could be explained by their p53 status, as p53 is a well-known sensor of mitotic failure27.
Figure 5. PP-13 is a microtubule-depolymerizing agent that competes with colchicine for tubulin binding. 
(A) Effect of PP-13 on microtubule dynamics assessed by an in vitro tubulin polymerization assay over time. 
Assembly of pure tubulin (40 µmol.L−1) in the presence of increasing concentrations of PP-13 (0 to 25 µmol.L−1) 
was followed by turbidimetry at 350 nm. DMSO, paclitaxel (5 µmol.L−1) and colchicine (2.5 µmol.L−1) were 
used as vehicle control, polymerizing and depolymerizing agents, respectively. Each turbidity value represents 
the mean ± SD from 3 independent experiments. (B) Representative transmission electron microscopy images 
showing the polymerization of tubulin (25 µmol.L−1) in the presence of DMSO, colchicine (2.5 µmol.L−1) or 
increasing concentrations of PP-13 (0 to 25 µmol.L−1). (C) Displacement of MTC from the colchicine binding 
site by PP-13. Fluorescence emission spectra (372–525 nm) of 10 µmol.L−1 MTC and 10 µmol.L−1 tubulin in 
the presence of increasing concentrations of PP-13 (0 to 50 µmol.L−1) are shown. Each fluorescence intensity 
value (in arbitrary unit, A.U.) represents the mean from 2 independent assays. Error bars are not shown for the 
sake of clarity. (D) Displacement of MTC from the colchicine-binding site by PP-13. MTC fractional saturation 
was calculated based on the concentration of MTC binding sites (0.8 per tubulin dimer) and the MTC binding 
constant (4.7× 105 M−1).
www.nature.com/scientificreports/
9SCIEnTIFIC RepoRts | 7: 10209  | DOI:10.1038/s41598-017-09491-9
In PP-13-treated cells, spindle multipolarity led to defects in chromosome alignment and spindle-kinetochore 
attachment. Thus, the lack of tension between the two sister kinetochores did not satisfy the spindle assembly 
checkpoint (SAC)28. This is most likely the reason for the prolonged mitotic arrest observed in live imaging of 
HeLa cells expressing the major component of the SAC BubR1. Using time-lapse videomicroscopy, we observed 
that cells finally exited from prolonged mitotic arrest with various cell fates, as described elsewhere29. We and oth-
ers30, 31 believe that the cell type might largely influence the cell outcome. We observed that half of HeLa cells died 
immediately during mitosis via mitotic catastrophe as evidenced by the presence of blebs, chromatin condensa-
tion and the release of apoptotic bodies, while the other cells (35%) escaped from the mitotic blockade through 
asymmetric division generating non-viable aneuploid cells. On the other hand, a large fraction of H358 cells 
(64%) exited mitosis without cell division (mitotic slippage), then died during interphase or a second mitosis.
Analysis of the effect of PP-13 on the kinetics of in vitro pure tubulin assembly indicated that PP-13 is able to 
inhibit tubulin assembly. This was confirmed by electron microscopy analysis of microtubules treated with PP-13. 
Competition experiments indicated that PP-13 binds tubulin at the colchicine-binding site, with an apparent 
Figure 6. PP-13 inhibits tumour growth and cell dissemination in vivo. H358 NSCLC cells were xenografted on 
a chick embryo chorioallantoic membrane (CAM). After treatment with vehicle (0.5% DMSO), paclitaxel (50 
µmol.L−1) or PP-13 (170 nmol.L−1), tumours were excised and weighed. (A) Schematic representation of the 
assay principle. (B) Representatives pictures of tumours at the end of the different treatments. Bar = 1 mm. (C) 
Effects of treatments on the H358 tumour weight (means ± SEM of ≥16 samples). (D) Effects of treatments on 
H358 metastasis in the lower CAM (means ± SEM of 15 samples). The presence of H358 cells in the lower CAM 
was evaluated by qPCR.
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binding affinity constant (Kb) of 9.3 × 104 M−1. The PP-13 Kb value can explain, at least in part, why the effects of 
PP-13 on microtubule organization are only observed in mitotic cells but not in interphase cells at the IC50. The 
mass action law predicts that only 1% of PP-13 binds to the available binding sites, since its IC50 is 100 times less 
than its dissociation constant (1/Kb). Since tubulin disassembly by colchicinoids is stoichiometric, PP-13 would 
not induce a visible effect in the polymer mass at IC50 concentrations during interphase. Since most neurons 
mainly remain in interphase, PP-13 could have a reduced possibility of causing neurotoxic side effects because of 
microtubule destabilization. This remains to be confirmed, but suggested a potential benefit for PP-13 anti-cancer 
activity, compared to taxanes and vinca-alkaloids that also affect interphase cells16, 32. It is worth noting that the 
only 1% of tubulin bound to PP-13 is sufficient to alter the microtubule dynamics essential for division. This could 
explain the effects observed in mitotic cells and the activation of the spindle assembly checkpoint. Thus, PP-13 
is nontoxic for interphasic cells because of its 10- to 100-fold lower microtubule dynamics compared to that in 
mitotic cells33.
In addition, the PP-13 affinity for tubulin is much lower than that described for podophyllotoxin 
(Kb = 1.8 × 106 M−1)34 and colchicine (Kb = 1.9 × 106–1.2 × 107 M−1)35. Such a lower affinity could be a favour-
able property as Kb has been shown to be correlated with tubulin ligand cytotoxicity25. This suggests that PP-13 
could be better tolerated than colchicine and podophyllotoxin whose toxicities (mostly myelosuppression and 
neurotoxicity) hamper their use as anti-cancer drugs.
Moreover, the Kb of PP-13 is in a range fairly similar to those of other well-known colchicine binding site lig-
ands, such as MTC (Kb = 4.7 × 105 M−1)36 and nocodazole (Kb = 4 × 105 M−1)37, indicating that PP-13 probably 
displays a sufficient affinity towards tubulin for its use as a promising antimitotic agent. Currently, a large number 
of tubulin colchicine site-binding agents are undergoing preclinical or clinical development16, 22, 38, 39. However, 
none of these agents display the same pyrrolopyrimidin scaffold as PP-13 that makes this compound an attractive 
candidate for further pre-clinical investigations.
It is widely known that solid malignancies are prone to develop acquired MDR after conventional chemother-
apy treatment, mainly because of overexpression of transmembrane efflux pumps, such as MRP1 MRP2, BCRP 
and P-glycoprotein40. In this context, there is a keen interest to develop therapeutic alternatives with high cytotox-
icity against MDR cancer cells. The recent FDA-approval of eribulin mesylate that overcome the MDR cell pheno-
type41, 42 illustrates this effort. In our study, PP-13 was shown to overcome efflux-mediated chemoresistance and 
could thus present a strong advantage over vinca-alkaloids that are actively effluxed by MRP1 and P-glycoprotein 
transporters or over taxanes that are exported by P-glycoprotein and MRP216.
To confirm the PP-13 anticancer effects in vivo that were observed in vitro, we used the model of tumour xeno-
grafts in the chorioallantoic membrane of living chick embryos. Such in ovo experiments are accepted as potential 
alternatives to mammalian models for the in vivo assessment of drug toxicity and pharmacokinetics43, especially 
in the cancerology field, since tumour implantation is facilitated by CAM physiological immunodeficiency44–46. 
This model also allows the evaluation of tumour metastatic invasion owing to the intense vascularization of the 
egg45. We showed that PP-13 at a concentration of 0.17 µmol.L−1 effectively inhibits in vivo tumour growth with 
no detectable toxicity for the growing embryo. PP-13 also significantly reduced tumour cell dissemination in vivo, 
which suggested potential antimetastatic effects.
In summary, we described a pyrrolopyrimidine derivative (PP-13) that inhibited the growth of a wide range 
of cancer cell types, including targeted therapy-resistant and multidrug-resistant (MDR) cell lines. PP-13 caused 
prometaphase arrest associated with aberrant multipolar mitotic spindles, microtubule disorganization, and acti-
vation of spindle assembly checkpoint proteins. In vitro experiments revealed that PP-13 directly inhibits micro-
tubule assembly by targeting the colchicine-binding site in β-tubulin. Finally, PP-13 exerted potent antitumour 
effects in vivo without noticeable toxicity in the chicken embryos. These findings suggest new prospects for PP-13 
that could represent a promising alternative to conventional spindle poisons, such as taxanes or vinca-alkaloids 
in the case of MDR cancer cells.
Methods
Chemical reagents, antibodies and proteins. Molecule PP-13 (purity >95% by liquid chromatogra-
phy – mass spectrometry) came from the Institut Curie (CNRS chemical library, 2004 version), was dissolved 
in anhydrous dimethyl sulfoxide (DMSO, Carl Roth, Karlsruhe, Germany) and stored in a 10 mmol.L−1 stock 
solution. Paclitaxel, colchicine, formaldehyde, and Hoechst 33342 were from Sigma-Aldrich (Saint Quentin 
Fallavier, France). The anti-α-tubulin and anti-actin antibodies were purchased from Santa Cruz (Clinisciences, 
Montrouge, France). The anti-γ-tubulin antibody was from Sigma. The anti-phospho-histone H3 and anti-cleaved 
caspase 3 (Asp175) antibodies were purchased from Cell Signaling (Ozyme, Saint Quentin Yvelines, France). Anti-
centrin-2 antibodies were from Merck Millipore (Molsheim, France). Goat anti-mouse Alexa Fluor-488 and 
anti-rabbit Alexa Fluor-568 secondary antibodies were obtained from Life Technologies (Saint-Aubin, France). 
The tubulin used in the tubulin polymerization assay was isolated by Ecrins Therapeutics Services from bovine 
brain as previously described47, while the tubulin used in transmission electron microscopy (TEM) and the com-
petition fluorescence assay was isolated from calf brains48, 49. The calf brains used to purify the tubulin were a kind 
donation of Ganadería Fernando Díaz. They come from 6 to 12 months old calfs sacrificed at the slaughterhouse 
Matadero Madrid-Norte S A Pol. Ind. Sur (Autovía Madrid-Burgos, 32,300, 28750 San Agustín del Guadalix, 
Madrid). These brains were extracted as other parts of the animals at the slaughterhouse following the com-
mercial procedures. Since the brains used were officially approved as meat for human consumption, no further 
permissions from a comitee were required.
Cell lines. NSCLC (H358, H322, A549, H1975, H1650, H3255, PC9 and H460), other human cancer cell lines 
from different organs (HCT116, HT29, MCF7, PC3, HeLa, colo829, A375, A7, NIH3T3, HEK293), human foetal 
lung fibroblast MRC5 cells, and human keratinocytes HaCat cells were obtained from the American Type Culture 
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Collection (ATCC, Manassas, VA, USA), routinely tested and authenticated by the ATCC, and cultured as rec-
ommended. HeLa cells expressing mEGFP-α-tubulin and mRFP-H2B were a generous gift from Dr D. Gerlich50. 
HeLa cells expressing GFP-BubR1 were kindly provided by Pr A. Musacchio51. H358 cells stably expressing 
RFP-Histone H2B or cell lines overexpressing P-glycoprotein, MRP1, MRP2, or ABCG2 transporter were gener-
ated and selected in our laboratories. All cells were mycoplasma-free, cultured at 37 °C in the appropriate medium 
in a 5% CO2 humidified atmosphere and used within 6 months after thawing.
Cell proliferation and apoptosis assays. Cell viability was analysed using the MTT assay as previously 
described52. Apoptotic cells with hypodiploid DNA staining were counted in “sub-G1” peaks using flow cytome-
try. Cleavage of caspase-3 was also detected by immunoblotting as previously described53.
Cell-cycle analysis. Cells were harvested, fixed in 70% ethanol at 4 °C, incubated with anti-phospho-histone 
3 Alexa Fluor 488-labelled antibodies diluted in 1% Foetal Bovine Serum (FBS)/0.25% Triton × 100/PBS for 1 h at 
room temperature, before staining with 20 µg.mL−1 propidium iodide in RNase A/PBS, as previously described54. 
The percentage of cells in the specific cell-cycle phases (G0/G1, S, G2, and M) was determined using an Accuri C6 
flow cytometer (Becton Dickinson, Le Pont-de-Claix, France).
Immunofluorescence analyses. Cells were grown on glass coverslips coated with 1 μg.mL−1 fibronectin, 
treated for 24 h, fixed and permeabilized with either 4% paraformaldehyde followed by 0.1% Triton × 100 incuba-
tion or with methanol at -20 °C. After washing and saturation with 5% BSA/PBS, cells were incubated for 1 h with 
primary antibodies (anti-α-tubulin, anti-γ-tubulin, anti-centrin-2 antibodies), washed twice again, and incu-
bated with Alexa Fluor 488 and/or Alexa Fluor 568 secondary antibodies for 45 min at RT. DNA was stained with 
20 µmol.L−1 Hoechst 33342, and coverslips were mounted with fluorescence mounting medium (DAKO, Trappes, 
France). Fluorescent images were captured using a multiphoton confocal laser-scanning microscope (LSM 510, 
Carl Zeiss, Jena, Germany) equipped with a Plan Apochromat 100×/1.4 NA oil objective and acquisition software 
LSM 510. All images are z-stacked.
Time-lapse videomicroscopy. HeLa cells expressing alpha-tubulin-EGFP H2B-mRFP or GFP-BubR1 
were seeded on 2-well LabTek slides (Nunc, D. Dutscher, Brumath, France) coated with 1 μg.mL−1 fibronectin 
and allowed to grow for 24 h prior to imaging. After treatment, the slide was placed on a 37 °C heated stage 
(at 5% CO2) and images were acquired every 3 min by a spinning disk confocal laser microscope (Andromeda 
iMIC, FEI, Munich, Germany) equipped with a Plan-Apochromat 40×/1.4 Oil objective and an EMCCD cam-
era (iXon3897, Andor, Belfast, UK). For each time point, a stack of 15 planes (thickness: 2 µm) was recorded. 
Acquisition (LA) and off-line analysis (OA) software programs were used.
Tubulin polymerization assay. The tubulin polymerization assay was performed by Ecrins Therapeutics 
Services (www.ecrins-therapeutics-services.com). Briefly, a half-area 96-well plate (Greiner Bio-one, 
Courtaboeuf, France) was charged with pure tubulin (40 µmol.L−1) in a PIPES-based polymerization buffer (80 
mM K-PIPES pH 6.8, 1 mM MgCl2, 1 mM EGTA). After the addition of 1 mmol.L−1 GTP, tubulin assembly was 
followed at 37 °C in the presence of colchicine, paclitaxel or increasing concentrations of PP-13, by turbidime-
try variation at 350 nm every 30sec during 1h (FLUOstar Omega, BMG Labtechnologies). The experiment was 
performed in triplicate. A negative control contained an equivalent quantity of DMSO as the sample with higher 
concentration of PP-13 (25 µmol.L−1). The solubility of the compound in the polymerization buffer was checked 
prior to the test.
Transmission electron microscopy (TEM). Tubulin assembly was performed in GAB buffer (3.4 mol.L−1 
glycerol, 10 mmol.L−1 sodium phosphate (NaPi), 1 mmol.L−1 EGTA, 6 mmol.L−1 MgCl2, 1 mmol.L−1 GTP, pH 
6.7) with 25 µmol.L−1 of pure tubulin and increasing amounts of PP-13. Samples were fixed with 0.1% glutaralde-
hyde. Subsequently, the reaction was stopped with 100 mmol.L−1 glycine, and then 4 µL of a 1/10 dilution in water 
of the sample was mounted into a carbon-coated 400 mesh copper grid. Samples were counterstained with 2% 
(w/v) uranyl acetate prior to examination using TEM. Micrographs were obtained using a JEOL 1230 transmis-
sion electron microscope at 100 KeV and a 16 megapixel TemCam-F416 camera from TVIPS.
Competition fluorescence assay. The tubulin target site of PP-13 and its associated binding affinity con-
stant (Kb) were determined by competitive assay using a fluorescent colchicine analogue MTC (2-methoxy-5-(2,3
,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one) that reversibly binds to the colchicine-binding site55, 56. Equal 
amounts of pure tubulin and MTC (10 µmol.L−1) were mixed in a phosphate-based buffer (10 mmol.L−1 NaPi, 
0.1 mmol.L−1 GTP). After addition of increasing concentrations of PP-13, the displacement of MTC binding 
to tubulin was measured by fluorescence changes using Fluoromax-2 (Jobin-Yvon SPEX, Longjumeau, France) 
(excitation wavelength: 350 nm, emission spectra: 372–525 nm). Tubulin and MTC alone served as negative 
controls for fluorescence normalization. Assuming 0.8 MTC sites per tubulin heterodimer and 4.7 × 105 M−1 as 
the MTC binding constant36, the PP-13 binding affinity constant was evaluated using the Equigra v5 program25.
In vivo experiments. A chick embryo tumour growth and metastasis assay (InOvotion, Grenoble, France) 
was performed as previously described44, 57, 58. According to the French legislation, no ethical approval is needed 
for scientific experimentations using oviparous embryos (decree n° 2013–118, February 1, 2013; art. R-214–88). 
Briefly, fertilized White Leghorn eggs (SFPA, Hendrix Genetics group, Saint Brieuc) were incubated at 38 °C with 
60% relative humidity for 9 days. The chorioallantoic membrane (CAM) was then dropped, and a 1-cm2 window 
was cut in the eggshell above the CAM (at day 9). H358 cells were harvested by trypsinization, washed with com-
plete medium, and suspended in serum-free medium. A 50 µL inoculatum of 1.106 H358 cells was added directly 
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onto the CAM of each egg. Eggs were randomly allocated into 3 groups of 17–19 eggs to get sufficient surviving 
embryos at the end of the experiments. At day 10, when tumours began to be detectable, eggs were treated every 
two days for 10 days by dropping 100 µL of either 50 µmol.L−1 paclitaxel, 0.17 µmol.L−1 PP-13 or 0.5% DMSO in 
PBS (vehicle) onto the tumour. The dropwise addition of a solution onto the large tumour area that depresses the 
CAM surface was found to be a suitable method, which avoided leakage and dispersion of the compounds. Then, 
the windows were sealed with cellophane tape and the eggs were returned to the incubator. At day 19, the upper 
portion of the CAM was removed and transferred to PBS, and the tumours were carefully cut away from normal 
CAM tissue and weighed. In parallel, a 1-cm2 portion of the lower CAM was collected to evaluate the number of 
H358 cells. To count these cells, genomic DNA was extracted, and qPCR analysis was performed by using primers 
specific for genomic human Alu/repetitive sequences59. Finally, the toxicity of the treatment was evaluated by 
scoring the number of dead embryos and looking for morphological or functional abnormalities in surviving 
embryos (Supplementary Fig. S12).
Statistical analysis. Continuous variables were compared using the non-parametric Mann-Whitney U-test 
or Kruskal-Wallis test. Categorical variables were compared using Fisher’s exact test. All analyses were performed 
using Statview software. Statistical significance was defined as p values <0.05.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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